EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Synergistic oral beta-lactam combinations for treating tuberculosis

Diana H Quan, Trixie Wang, Elena Martinez, Hannah Y Kim, Vitali Sintchenko, Warwick J Britton, James A Triccas, Jan-Willem C Alffenaar

Journal of Applied Microbiology · 03.10.2024 · 135 (10)

DOI: 10.1093/jambio/lxae255 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Applied Microbiology, online erschienen am 11.10.2024. Verfasst von Diana H Quan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Tuberculosis Research Program, Centenary Institute, The University of Sydney, 2006 NSW, Australia. Hauptthemen laut MEDLINE: beta-Lactams, Drug Synergism, Microbial Sensitivity Tests, Mycobacterium tuberculosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHMRC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The enormous burden of tuberculosis (TB) worldwide is a major challenge to human health, but the costs and risks associated with novel drug discovery have limited treatment options for patients. Repurposing existing antimicrobial drugs offers a promising avenue to expand TB treatment possibilities. This study aimed to explore the activity and synergy of beta-lactams in combination with a beta-lactamase inhibitor, which have been underutilized in TB treatment to date.

Methods

Based on inhibitory concentration, oral bioavailability, and commercial availability, seven beta-lactams (cefadroxil, tebipenem, cephradine, cephalexin, cefdinir, penicillin V, and flucloxacillin), two beta-lactamase inhibitors (avibactam and clavulanate), and three second-line TB drugs (moxifloxacin, levofloxacin, and linezolid) were selected for combination in vitro testing against Mycobacterium tuberculosis H37Rv. Resazurin assays and colony forming unit enumeration were used to quantify drug efficacy, Chou-Talalay calculations were performed to identify drug synergy and Chou-Martin calculations were performed to quantify drug dose reduction index.

Results

The order of activity of beta-lactams was cefadroxil > tebipenem > cephradine > cephalexin > cefdinir > penicillin V > flucloxacillin. The addition of clavulanate improved beta-lactam activity to a greater degree than the addition of avibactam. As a result, avibactam was excluded from further investigations, which focused on clavulanate. Synergy was demonstrated for cefdinir/cephradine, cefadroxil/tebipenem, cefadroxil/penicillin V, cefadroxil/cefdinir, cephalexin/tebipenem, cephalexin/penicillin V, cephalexin/cefdinir, cephalexin/cephradine, and cefadroxil/cephalexin, all with clavulanate. However, combining beta-lactams with moxifloxacin, levofloxacin, or linezolid resulted in antagonistic effects, except for the combinations of penicillin V/levofloxacin, penicillin V/moxifloxacin, and cefdinir/moxifloxacin.

Conclusions

Beta-lactam synergy may provide viable combination therapies for the treatment of TB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-LactamsDrug SynergismMicrobial Sensitivity TestsMycobacterium tuberculosisAntitubercular AgentsHumansbeta-Lactamase InhibitorsDrug Therapy, CombinationTuberculosisLevofloxacinAzabicyclo CompoundsLinezolidMoxifloxacinDrug CombinationsAdministration, Oral

Stichwörter der Autor:innen

beta-lactamcombination therapysynergytuberculosis

Substanzen

beta-LactamsAntitubercular Agentsbeta-Lactamase InhibitorsLevofloxacinAzabicyclo CompoundsLinezolidMoxifloxacinDrug Combinationsavibactam

Autor:innen und Institutionen

  • Tuberculosis Research Program, Centenary Institute, The University of Sydney, 2006 NSW, Australia.
  • Centre for Infectious Diseases and Microbiology, The Westmead Institute, 2145 NSW, Australia.
  • School of Pharmacy, The University of Sydney, 2006 NSW, Australia.
  • Sydney Infectious Diseases Institute, Faculty of Medicine and Health, The University of Sydney, Camperdown, 2006 NSW, Australia.
  • School of Medical Sciences, Faculty of Medicine and Health, Camperdown, 2006 NSW, Australia.
  • Department of Clinical Immunology, Royal Prince Alfred Hospital, Sydney, 2050 NSW, Australia.

Förderung

  • NHMRC

Zitieren

APA

Quan, D. H., Wang, T., Martinez, E., Kim, H. Y., Sintchenko, V., Britton, W. J., Triccas, J. A., & Alffenaar, J. C. (2024). Synergistic oral beta-lactam combinations for treating tuberculosis. Journal of Applied Microbiology, 135(10). https://doi.org/10.1093/jambio/lxae255

Vancouver

Quan DH, Wang T, Martinez E, Kim HY, Sintchenko V, Britton WJ, et al. Synergistic oral beta-lactam combinations for treating tuberculosis. Journal of Applied Microbiology. 2024;135(10). doi:10.1093/jambio/lxae255

BibTeX
@article{Quan2024,
  author = {Quan, Diana H and Wang, Trixie and Martinez, Elena and Kim, Hannah Y and Sintchenko, Vitali and Britton, Warwick J and Triccas, James A and Alffenaar, Jan-Willem C},
  title = {Synergistic oral beta-lactam combinations for treating tuberculosis},
  journal = {Journal of Applied Microbiology},
  year = {2024},
  volume = {135},
  number = {10},
  doi = {10.1093/jambio/lxae255}
}
Kostenlos starten →